Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-78934804 versus active control in moderately to severely active ulcerative colitis
2026-525923-26-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 33
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing JNJ-78934804, guselkumab and golimumab (3 arms). Primary endpoint: Clinical remission at Week 48. Planned start Aug 2026; status: authorised.
02
Drugs
guselkumab + golimumabguselkumabgolimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2026-525923-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525923-26-00.